Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Toyama Chemical gets Japanese rights to Cempra's solithromycin

Executive Summary

Antibiotics developer Cempra Inc. has licensed Toyama Chemical Co. Ltd. (majority owned by Fujifilm Holdings Corp.) exclusive rights to develop and commercialize in Japan its solithromycin (CEM101)--or any product that incorporates the active pharmaceutical ingredient--for all indications except ophthalmic.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies